TY - JOUR
T1 - Effect modification of the association between total cigarette smoking and ALS risk by intensity, duration and time-since-quitting
T2 - Euro-MOTOR
AU - Peters, Susan
AU - Visser, Anne E
AU - D'Ovidio, Fabrizio
AU - Vlaanderen, Jelle
AU - Portengen, Lützen
AU - Beghi, Ettore
AU - Chio, Adriano
AU - Logroscino, Giancarlo
AU - Hardiman, Orla
AU - Pupillo, Elisabetta
AU - Veldink, Jan H
AU - Vermeulen, Roel
AU - van den Berg, Leonard H
N1 - Funding Information:
This work was supported by funding from the European Community's Health Seventh Framework Programme (FP7/2007-2013, grant number 259867); and the Netherlands ALS Foundation.
Funding Information:
This work was supported by funding from the European Community's Health Seventh Framework Programme (FP7/2007-2013, grant number 259867); and the Netherlands ALS Foundation.
Funding Information:
EB reports grants from UCB-PHARMA, personal fees from MA-Provider, grants from American ALS Association, grants from EISAI, grants from Shire. AC reports personal fees from Biogen, grants from Italfarmaco, personal fees from Roche, personal fees from Cytokinetics, personal fees from Mitsubishi Tanabe. OH has received speaking honoraria from Novartis, Biogen Idec, Sanofi Aventis and Merck-Serono; and has been a member of advisory panels for Biogen Idec, Allergen, Ono Pharmaceuticals, Novartis, Cytokinetics and Sanofi Aventis. LvdB serves on scientific advisory boards for the Prinses Beatrix Spierfonds, Thierry Latran Foundation, Biogen, Cytokinetics, Orion and Sarepta. SP, AEV, FD, JV, LP, GL, EP, JHV and RV report no potential conflicts of interest.
Publisher Copyright:
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2020/1
Y1 - 2020/1
N2 - Background We investigated the association between cigarette smoking and risk of amyotrophic lateral sclerosis (ALS) in a pooled analysis of population-based case-control studies and explored the independent effects of intensity, duration and time-since-quitting. Methods ALS cases and controls, matched by age, sex and region, were recruited in the Netherlands, Italy and Ireland (∗Euro-MOTOR project). Demographics and detailed lifetime smoking histories were collected through questionnaires. Effects of smoking status, intensity (cigarettes/day), duration (years), pack-years and time-since-quitting (years) on ALS risk were estimated using logistic regression models, adjusting for age, sex, alcohol, education and centre. We further investigated effect modification of the linear effects of pack-years by intensity, duration and time-since-quitting using excess OR (eOR) models. Results Analyses were performed on 1410 cases and 2616 controls. Pack-years were positively associated with ALS risk; OR=1.26 (95%CI: 1.03 to 1.54) for the highest quartile compared with never smokers. This association appeared to be predominantly driven by smoking duration (p trend=0.001) rather than intensity (p trend=0.86), although the trend for duration disappeared after adjustment for time-since-quitting. Time-since-quitting was inversely related to ALS (p trend <0.0001). The eOR decreased with time-since-quitting smoking, until about 10 years prior to disease onset. High intensity smoking with shorter duration appeared more deleterious than lower intensity for a longer duration. Conclusions Our findings provide further support for the association between smoking and ALS. Pack-years alone may be insufficient to capture effects of different smoking patterns. Time-since-quitting appeared to be an important factor, suggesting that smoking may be an early disease trigger.
AB - Background We investigated the association between cigarette smoking and risk of amyotrophic lateral sclerosis (ALS) in a pooled analysis of population-based case-control studies and explored the independent effects of intensity, duration and time-since-quitting. Methods ALS cases and controls, matched by age, sex and region, were recruited in the Netherlands, Italy and Ireland (∗Euro-MOTOR project). Demographics and detailed lifetime smoking histories were collected through questionnaires. Effects of smoking status, intensity (cigarettes/day), duration (years), pack-years and time-since-quitting (years) on ALS risk were estimated using logistic regression models, adjusting for age, sex, alcohol, education and centre. We further investigated effect modification of the linear effects of pack-years by intensity, duration and time-since-quitting using excess OR (eOR) models. Results Analyses were performed on 1410 cases and 2616 controls. Pack-years were positively associated with ALS risk; OR=1.26 (95%CI: 1.03 to 1.54) for the highest quartile compared with never smokers. This association appeared to be predominantly driven by smoking duration (p trend=0.001) rather than intensity (p trend=0.86), although the trend for duration disappeared after adjustment for time-since-quitting. Time-since-quitting was inversely related to ALS (p trend <0.0001). The eOR decreased with time-since-quitting smoking, until about 10 years prior to disease onset. High intensity smoking with shorter duration appeared more deleterious than lower intensity for a longer duration. Conclusions Our findings provide further support for the association between smoking and ALS. Pack-years alone may be insufficient to capture effects of different smoking patterns. Time-since-quitting appeared to be an important factor, suggesting that smoking may be an early disease trigger.
KW - amyotrophic lateral sclerosis
KW - case-control study
KW - pooled analysis
KW - tobacco
UR - http://www.scopus.com/inward/record.url?scp=85071113636&partnerID=8YFLogxK
U2 - 10.1136/jnnp-2019-320986
DO - 10.1136/jnnp-2019-320986
M3 - Article
C2 - 31434759
SN - 0022-3050
VL - 91
SP - 33
EP - 39
JO - Journal of neurology, neurosurgery, and psychiatry
JF - Journal of neurology, neurosurgery, and psychiatry
IS - 1
ER -